Keros director buys 1,000 shares in open market
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock in an open‑market transaction at a weighted average price of $10.19 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock in an open‑market transaction at a weighted average price of $10.19 per share. After this buy, he directly holds 17,592 common shares. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre‑scheduled rather than a discretionary trade.
Insider Trade Summary 10b5-1
Net Buyer: 1,000 shares
Net Buy
1 txn
Insider
BIENAIME JEAN JACQUES
Role
Director
Bought
1,000 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $10.19 | $10K |
Holdings After Transaction:
Common Stock — 17,592 shares (Direct)
Footnotes (2)
- F1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Key Figures
Shares purchased: 1,000 shares
Weighted average price: $10.19 per share
Post-transaction holdings: 17,592 shares
+2 more
5 metrics
Shares purchased
1,000 shares
Open-market common stock buy on 2026-06-15
Weighted average price
$10.19 per share
Price for 1,000-share open-market purchase
Post-transaction holdings
17,592 shares
Common stock directly owned after transaction
Trade price range
$9.99–$10.34 per share
Range of individual executions for purchased shares
Plan adoption date
December 5, 2025
Rule 10b5-1 trading plan adoption by reporting person
Key Terms
Rule 10b5-1 trading plan, weighted average price, open-market purchase, Form 4
4 terms
Rule 10b5-1 trading plan regulatory
"Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Keros Therapeutics (KROS) disclose in this Form 4?
Keros Therapeutics reported that director Jean Jacques Bienaime bought 1,000 shares of common stock. The open‑market purchase occurred at a weighted average price of $10.19 per share and was executed under a pre‑arranged Rule 10b5-1 trading plan adopted in December 2025.
Was the Keros Therapeutics (KROS) insider trade made under a Rule 10b5-1 plan?
Yes. A footnote states the 1,000 Keros shares were purchased pursuant to a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on December 5, 2025, indicating the trades were pre‑scheduled rather than timed in response to recent market developments.
What does the reported price range mean for the Keros Therapeutics (KROS) insider purchase?
The Form 4 shows a weighted average price of $10.19 but notes trades occurred between $9.99 and $10.34. This means the 1,000 shares were bought in multiple executions inside that range, and detailed per‑price information is available upon request from the issuer or the SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates